Lilly drug chosen for Alzheimer’s prevention study
by Marilynn Marchione, AP Chief Medical Writer
January 18, 2013 02:45 PM | 796 views | 0 0 comments | 5 5 recommendations | email to a friend | print
Researchers have chosen an experimental drug by Eli Lilly & Co. for a large federally funded study aiming to prevent Alzheimer’s disease in older people at high risk of developing it.

The drug, called solanezumab (sol-ah-NAYZ-uh-mab), is designed to bind to and help clear the sticky deposits that clog patients’ brains.

Earlier studies found it did not help people with moderate to severe Alzheimer’s but it showed some promise against milder disease.

Researchers think it might work better if given before symptoms start. The new study will test it in 1,000 people ages 70 and older whose brain scans show plaque buildup but who do not yet have any symptoms of dementia.

Comments
(0)
Comments-icon Post a Comment
No Comments Yet
*We welcome your comments on the stories and issues of the day and seek to provide a forum for the community to voice opinions. All comments are subject to moderator approval before being made visible on the website but are not edited. The use of profanity, obscene and vulgar language, hate speech, and racial slurs is strictly prohibited. Advertisements, promotions, and spam will also be rejected. Please read our terms of service for full guides